InMed Pharmaceuticals Inc. (TSX:IN; OTCQB:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and biosynthesis platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, announced that the Company will ring the opening bell at the Toronto Stock Exchange today in honor of its migration to the exchange on March 26, 2018.
Eric A. Adams, InMed's President and Chief Executive Officer, stated, "As the Company continues to build recognition in the capital markets and grow its exposure to a broader and more diverse investor audience, we're proud to celebrate our successful migration to the TSX today." Mr. Adams continued, "I would also like to take this opportunity to acknowledge and thank our employees, investors and partners who have supported InMed in our many accomplishments to date. The integration of our proprietary drug-disease targeting platform and novel biosynthesis process, which we anticipate will deliver therapeutic compounds designed to treat multiple diseases with high unmet medical needs, is genuinely disruptive in the emerging cannabinoid space" concluded Mr. Adams.
About InMed:
InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed's proprietary bioinformatics platform, its biosynthesis manufacturing process and its drug development programs are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com.
SOURCE
Read More
InMed Rings the Opening Bell at the Toronto Stock Exchange
